Report error Found 19 Enz. Inhib. hit(s) with all data for entry = 11859
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 108nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 158nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 190nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 293nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 308nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 332nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 360nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 368nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 426nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 474nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 523nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 696nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 777nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 1.19E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 1.38E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 1.95E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Consejo Superior De Investigaciones Cientificas
US Patent
Consejo Superior De Investigaciones Cientificas
US Patent
Affinity DataIC50: 4.00E+3nMAssay Description:The compounds were evaluated in LRRK2 and in the mutated form LRRK2 G2019S. This mutation is more frequent in the familial forms of Parkinson's D...More data for this Ligand-Target Pair
